Type to search

Drug Development Industry News Mergers & Aquisitions News

BioIVT Acquires XenoTech, a Leading Provider of Products and Services for Preclinical Testing of New Drug Candidates

Share
BioIVT Acquires XenoTech, a Leading Provider of Products and Services for Preclinical Testing of New Drug Candidates | Pharmtech Focus

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired XenoTech, a provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, based in Japan. XenoTech specializes in ADME, DMPK and DDI testing of potential drug candidates.

This transaction demonstrates BioIVT’s continuing commitment to provide its biopharmaceutical customers with a comprehensive portfolio of research models and services to help them reach their R&D goals faster.

“XenoTech has a well-established and excellent reputation for producing microsomes, subcellular fractions, and for designing and implementing ADME-Tox studies on a contract research basis,” said BioIVT Chief Executive Officer (CEO) Dr. Richard Haigh. “The XenoTech and BioIVT product portfolios are complementary, and when combined, will enable smarter science and accelerate medical breakthroughs that enhance and extend lives by delivering personalized biospecimen solutions to life science and diagnostic industries. We are also delighted to have this opportunity to expand our highly respected scientific team with the addition of experienced researchers from XenoTech.”

“My colleagues and I are looking forward to joining BioIVT and starting the next exciting phase of our corporate growth,” said Dr. Darren Warren, CEO of XenoTech. “We built our business by taking a consultative approach to everything we do, whether it is helping researchers identify products with the right characteristics or recommending specific study programs. BioIVT shares our commitment to science and producing high quality products, and our desire to partner with drug researchers in their quest to develop new therapies to meet unmet medical needs.”

XenoTech’s product lines, which include best-in-class microsomes, complement BioIVT’s portfolio of hepatocytes and other hepatic products. XenoTech’s expertise also combines well with BioIVT’s strengths in drug transporter research, B-CLEAR® disposition studies, long-term HEPATOPAC® models, and other proprietary methodologies and will increase BioIVT’s capabilities to support and accelerate customer research.

XenoTech will continue to operate out of its headquarters in Kansas City, KS. Financial details about this transaction were not disclosed.

Tags:

People in this post:

Companies in this post:

You Might also Like

Related Stories

Next Up